A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Lenalidomide (Primary) ; Spebrutinib (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms CLEAR
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2019 to 1 Jun 2018.
- 20 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Nov 2014.